Editor’s Note: In a new white paper, summarized below, Manatt Health discusses emerging reimbursement models for cell and gene therapies. The paper provides an overview of current Medicaid, Medicare and commercial coverage,...more
7/26/2023
/ Centers for Medicare & Medicaid Services (CMS) ,
DNA ,
Food and Drug Administration (FDA) ,
Genetic Materials ,
Health Insurance ,
Healthcare ,
Life Sciences ,
Medicaid ,
Medicare ,
Pharmaceutical Industry ,
Value-Based Payments
Over the past five years, cell and gene therapies have increasingly moved from the R&D pipeline to the health care setting, putting lifesaving treatments for certain cancers and genetic diseases within patients’ reach. Over...more
7/20/2023
/ Clinical Trials ,
Food and Drug Administration (FDA) ,
Health Insurance ,
Healthcare ,
Human Genes ,
Life Sciences ,
Medicaid ,
Medical Devices ,
Medical Reimbursement ,
Medical Research ,
Medicare ,
Pharmaceutical Industry